Fig. 5: Differences in AMAN and CLZ efficacy based on behavioral features. | npj Parkinson's Disease

Fig. 5: Differences in AMAN and CLZ efficacy based on behavioral features.

From: A spatiotemporal hypergraph self-attention neural networks framework for the identification and pharmacological efficacy assessment of Parkinson’s disease motor symptoms

Fig. 5

A AMAN and CLZ dosing schedules. B Time series of mouse behavioral features after AMAN and CLZ administration. C Changes in 15 behavioral features within 3 h after AMAN and CLZ administration (LID = 12, AMAN = 6, CLZ = 6) (****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, Kolmogorov–Smirnov test, Bonferroni correction). D Three differential efficacy features after AMAN and CLZ treatment among the representative features of LID. E Behavioral transition chord diagrams for mice after AMAN and CLZ administration. Each chord in the diagram represents a behavioral switch from a previous state to a subsequent state, with colors corresponding to the initial state and line thickness reflecting the frequency of that transition type (I, AMAN; II, CLZ; III, LID). F Differences in behavioral transitions between AMAN and LID as well as CLZ and LID. The vertical axis represents the initial state, and the horizontal axis represents the subsequent state. The color intensity indicates the normalized average transition difference (calculated as AMAN minus LID and CLZ minus LID) (I, AMAN-LID; II, CLZ-LID).

Back to article page